share_log

亚盛医药-B(06855):三项临床前进展将在2024年美国癌症研究协会年会上公布

Yasheng Pharmaceutical-B (06855): Three pre-clinical advances will be announced at the 2024 American Association for Cancer Research Annual Meeting

Zhitong Finance ·  Mar 5 18:46

Yasheng Pharmaceutical-B (06855) announced that the company selected three preclinical research advances for 2024 American Cancer...

Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) announced that the company's three preclinical research advances were selected for the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), involving the company's original Class 1 drug olevatinib (product name: Nellick; R&D code: HQP1351), MDM2-p53 inhibitor APG-115, FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the embryonic ectodermal development protein (EED) inhibitor APG-1859. The summary is now published on AACR's official website.

The American Association for Cancer Research (AACR) Annual Meeting is one of the oldest and largest academic conferences on cancer research in the world. The conference focuses on all aspects of high-quality oncology research and innovation. It is the focus of global oncology research and will bring together cutting-edge research results in the field of oncology. This year's AACR Annual Meeting will be held from April 5, 2024 to April 10, 2024 ET in San Diego, California, USA.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment